Inotiv, Inc.

NasdaqCM:NOTV 株式レポート

時価総額：US$10.0m

Inotiv 将来の成長

Future 基準チェック /06

Inotivは、20.6%と5.6%でそれぞれ年率20.6%で利益と収益が成長すると予測される一方、EPSはgrowで21.5%年率。

主要情報

20.6%

収益成長率

21.54%

EPS成長率

Life Sciences 収益成長17.5%
収益成長率5.6%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日09 Feb 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 15

NOTV: Improving Margins And Higher Future P/E Will Support Upside

Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.
ナラティブの更新 • Apr 29

NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E

Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.
ナラティブの更新 • Apr 15

NOTV: Margin Execution And Higher Future P/E Will Support Upside

Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
ナラティブの更新 • Apr 01

NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement

Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.
ナラティブの更新 • Mar 18

NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance

Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
ナラティブの更新 • Mar 06

The Global Shortage of Research Primates and Why It May Matter for Inotiv

Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.
ナラティブの更新 • Mar 04

The Hidden Scientific Infrastructure Behind Inotiv.

Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.
ナラティブの更新 • Mar 04

NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk

Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.
ナラティブの更新 • Feb 23

Why March 6 and March 31 Matter

— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.
ナラティブの更新 • Feb 17

NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration

Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.
ナラティブの更新 • Feb 13

Inotiv's Margin Discipline Will Reshape Its Financial Future

Inotiv does not need perfection. It needs margin discipline.
新しいナラティブ • Feb 11

Inotiv NAMs Test Center

Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.
ナラティブの更新 • Feb 03

NOTV: Raised Fair Value Will Rely On AI Collaboration Execution

Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).
ナラティブの更新 • Jan 20

NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk

Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.
ナラティブの更新 • Jan 06

NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk

Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).
ナラティブの更新 • Dec 19

NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk

Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).
ナラティブの更新 • Dec 05

NOTV: Future Margins And Legal Settlement Will Support Share Upside

Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.
分析記事 • Jun 27

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump

Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...
分析記事 • May 03

Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump

Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...
分析記事 • Apr 25

Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
User avatar
新しいナラティブ • Apr 06

NHP Facilities And North American Optimization Will Secure Stability

Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.
分析記事 • Mar 11

Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower

To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...
分析記事 • Dec 06

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Apr 26

Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues

The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...
分析記事 • Mar 19

Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Feb 13

Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...
分析記事 • Dec 18

Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...
分析記事 • Dec 13

Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...
分析記事 • Nov 21

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Aug 14

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

業績と収益の成長予測

NasdaqCM:NOTV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
9/30/2028587N/A30N/A1
9/30/2027558-6311N/A2
9/30/2026530-785N/A2
3/31/2026507-87-140N/A
12/31/2025514-69-29-11N/A
9/30/2025513-69-27-10N/A
6/30/2025505-79-46-27N/A
3/31/2025480-87-54-34N/A
12/31/2024475-121-26-5N/A
9/30/2024491-108-29-7N/A
6/30/2024501-99-914N/A
3/31/2024553-711033N/A
12/31/2023585-33429N/A
9/30/2023572-105028N/A
6/30/2023582-340-179N/A
3/31/2023597-345-42-4N/A
12/31/2022586-341-50-11N/A
9/30/2022548-337-42-5N/A
6/30/2022427-83-38-3N/A
3/31/2022277-77-1510N/A
12/31/2021156-72-98N/A
9/30/20219011-211N/A
6/30/2021750-28N/A
3/31/202168-405N/A
12/31/202065-4-41N/A
9/30/202060-5-51N/A
6/30/202059-3-62N/A
3/31/202055-2-71N/A
12/31/201948-2N/A2N/A
9/30/201944-1N/A2N/A
6/30/201938-1N/A3N/A
3/31/201933-1N/A4N/A
12/31/2018300N/A4N/A
9/30/2018260N/A3N/A
6/30/2018230N/A2N/A
3/31/2018231N/A2N/A
12/31/2017231N/A1N/A
9/30/2017241N/A1N/A
6/30/201724-1N/A2N/A
3/31/201723-2N/A1N/A
12/31/201622-3N/A2N/A
9/30/201620-3N/A1N/A
6/30/201620-2N/A1N/A
3/31/2016210N/A2N/A
12/31/2015220N/A2N/A
9/30/2015231N/A2N/A
6/30/2015241N/A2N/A

アナリストによる今後の成長予測

収入対貯蓄率: NOTV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NOTV今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NOTV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NOTVの収益 ( 5.6% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: NOTVの収益 ( 5.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NOTVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/17 03:56
終値2026/05/15 00:00
収益2026/03/31
年間収益2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Inotiv, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Matthew HewittCraig-Hallum Capital Group LLC
David WindleyJefferies LLC
Jeffrey CohenLadenburg Thalmann & Company